Catalog No.: PC-63499Not For Human Use, Lab Use Only.
Zipalertinib (TAS6417, CLN-081) is a novel potent, selective inhibitor of EGFR exon 20 insertion mutations with IC50 of 1.1-8.0 nM, >100-fold selectivity over WT EGFR.
Zipalertinib (TAS6417, CLN-081) is a novel potent, selective inhibitor of EGFR exon 20 insertion mutations with IC50 of 1.1-8.0 nM, >100-fold selectivity over WT EGFR.
Zipalertinib (TAS6417) fits into the ATP-binding site of the EGFR hinge region.
Zipalertinib (TAS6417) inhibits EGFR phosphorylation and downstream molecules in NSCLC cell lines expressing EGFR exon 20 insertions (IC50=20-100 nM), resulting in caspase activation.
Zipalertinib (TAS6417) inhibits the proliferation of Ba/F3 cells driven by various EGFR exon 20 insertion mutations with IC50 of 5.05-150 nM.
Zipalertinib (TAS6417) causes persistent tumor regression in vivo in EGFR exon 20 insertion-driven tumor models.
